Neumora reports Q4 2023 net loss of $108.7M; cash $463.8M into 2026

Neumora Therapeutics, Inc.

Net loss Q4 2023: $108.7M vs $28.1M in Q4 2022; full year net loss $235.9M vs $130.9M.
Cash, cash equivalents and marketable securities $463.8M as of Dec 31, 2023; expected to fund operations into 2026.
R&D expenses Q4 2023: $38.9M, up from $23.5M, driven by navacaprant Phase 3 startup and IPR&D costs.
Topline Phase 3 KOASTAL-1 data for navacaprant in MDD expected H2 2024; KOASTAL-2/3 data in H1 2025.
Phase 1 data for NMRA-266 (M4 PAM) in healthy adults expected mid-2024; Phase 1b in schizophrenia planned H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Neumora Therapeutics, Inc. reported financial results for fiscal year ended December 31, 2023.

Period: fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 7, 2024, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-061473

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.